BRPI0513862A - métodos de tratar condições oftálmicas - Google Patents

métodos de tratar condições oftálmicas

Info

Publication number
BRPI0513862A
BRPI0513862A BRPI0513862-0A BRPI0513862A BRPI0513862A BR PI0513862 A BRPI0513862 A BR PI0513862A BR PI0513862 A BRPI0513862 A BR PI0513862A BR PI0513862 A BRPI0513862 A BR PI0513862A
Authority
BR
Brazil
Prior art keywords
methods
therapeutic agents
ophthalmic conditions
treating ophthalmic
individual
Prior art date
Application number
BRPI0513862-0A
Other languages
English (en)
Inventor
William A Hare
Elizabeth Wolde Mussie
Larry A Wheeler
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0513862A publication Critical patent/BRPI0513862A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

MéTODOS DE TRATAR CONDIçõES OFTáLMICAS. Métodos de tratar condições oftálmicas incluem administrar um ou mais agentes terapêuticas a um indivíduo. Em um aspecto, um método inclui administrar um ou mais agentes terapêuticos de uma vez quando o indivíduo não está ciente de uma perda do campo visual associada com a condição oftálmica. Em outro aspecto, um método inclui administrar um ou mais agentes terapêuticas a um indivíduo com uma condição oftálmica associada com neurodegeneração retinal, em que a administração do agente terapêutico é eficaz na redução de uma diminuição em uma resposta do sistema nervoso central associada com a neurodegeneração retinal.
BRPI0513862-0A 2004-07-26 2005-07-26 métodos de tratar condições oftálmicas BRPI0513862A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59142304P 2004-07-26 2004-07-26
PCT/US2005/026703 WO2006015075A1 (en) 2004-07-26 2005-07-26 Methods of treating ophthalmic conditions

Publications (1)

Publication Number Publication Date
BRPI0513862A true BRPI0513862A (pt) 2008-05-20

Family

ID=35160080

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513862-0A BRPI0513862A (pt) 2004-07-26 2005-07-26 métodos de tratar condições oftálmicas

Country Status (6)

Country Link
EP (1) EP1776097A1 (pt)
JP (1) JP2008507588A (pt)
AU (1) AU2005269293A1 (pt)
BR (1) BRPI0513862A (pt)
CA (1) CA2575204A1 (pt)
WO (1) WO2006015075A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US20070203144A1 (en) * 2006-01-17 2007-08-30 Allergan, Inc. Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals
ES2758554T3 (es) 2009-12-08 2020-05-05 Univ Case Western Reserve Aminoácidos gama para tratamiento de trastornos oculares

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5597809A (en) * 1994-06-23 1997-01-28 Massachusetts Eye & Ear Infirmary Treatment of optic neuritis
WO1997038691A1 (en) * 1996-04-17 1997-10-23 Sumitomo Pharmaceuticals Co., Ltd. Remedy for retinal neuropathy
US20050009884A1 (en) * 1997-06-30 2005-01-13 Dreyer Evan B. Calcium blockers to treat proliferative retinal diseases
AU727080B2 (en) * 1997-06-30 2000-11-30 Allergan, Inc. Calcium blockers to treat proliferative vitreoretinopathy
AU9797598A (en) * 1997-11-14 1999-06-07 Alcon Laboratories, Inc. Treatment of diabetic retinopathy
HK1040184A1 (zh) * 1999-03-12 2002-05-31 Alcon Laboratories, Inc. 治療青光眼之組合療法
US20030119846A1 (en) * 2000-03-17 2003-06-26 Collier Jr Robert J. Compounds with 5-ht activity useful for controlling visual field loss
US20030082183A1 (en) * 2000-11-01 2003-05-01 Wheeler Larry A. Methods and compositions for treatment of ocular neovascularization and neural injury
US6761694B2 (en) * 2001-12-13 2004-07-13 Allergan, Inc. Methods for measuring retinal damage
US20050031652A1 (en) * 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers

Also Published As

Publication number Publication date
AU2005269293A1 (en) 2006-02-09
CA2575204A1 (en) 2006-02-09
JP2008507588A (ja) 2008-03-13
EP1776097A1 (en) 2007-04-25
WO2006015075A1 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
Krolick et al. Effects of estrogens on central nervous system neurotransmission: implications for sex differences in mental disorders
Carretero et al. Guidelines for the use of acitretin in psoriasis
EP4487908A3 (en) Methods of treating crohn's disease and ulcerative colitis
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
MY174080A (en) Use of dpp iv inhibitors
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
BR112015001158A2 (pt) formulação oftálmica e respectivo uso e método para melhorar, reduzir ou tratar presbiopia
AR043188A1 (es) Metodos y composiciones para el tratamiento de enfermedades y trastornos asociados con niveles elevados de citoquinas proinflamatorias
BRPI1011031A2 (pt) sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste.
WO2007103373A3 (en) Compositions and methods for the treatment of immunoinflammatory disorders
MX391565B (es) Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
BR0308482A (pt) Sistema de administração de droga implantável
MY175997A (en) Antl-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig protein scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
WO2009073544A3 (en) Methods for treating a disorder by regulating gprc6a
PE20110711A1 (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmaceuticamente aceptables de la misma
SG10201906172XA (en) Regulation of glucose metabolism using anti-cgrp antibodies
MX2020001342A (es) Uso de gaboxadol en el tratamiento contra diabetes y afecciones relacionadas.
WO2005087210A3 (en) Prevention of retinopathy by inhibition of the visual cycle
MX2024010539A (es) Metodos para tratar enfermedades asociadas con ciliopatias.
Zhou et al. Antibiotic prophylaxia in patients with severe acute pancreatitis
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
BRPI0513862A (pt) métodos de tratar condições oftálmicas
BRPI0519016A2 (pt) agente preventivo ou terapÊutico para distérbios do sono, uso de uma droga, e, mÉtodo para prevenÇço e/ou tratamento de distérbios do sono
CO2020000529A2 (es) Metodos para tratar hiperinsulinismo congenito

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired